EGFR and non-small cell lung carcinoma: Meanwhile, the LUARA study has ushered in a new era of EGFR‐TKI consolidation for EGFR‐mutant, unresectable NSCLC,[23] and the role of ctDNA and PET parameters in guiding consolidation therapy for these patients requires further investigation.